Related resources and publications
VISTA - safety and PK profiling
Humanized ICP mouse and cell lines
PLoS One
J Allergy Clin Immunol
J Immunother Cancer
Nat Cancer
The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.
The double-humanized PD‑1 and PD-L1 (hPD-1/hPD-L1) mouse model was generated by intercrossing hPD-1 and hPD-L1 mice.
The PD-1 humanized model, developed by Knockin at the mouse Pd-1 locus, expresses a chimeric PD-1: human extracellular and mouse transmembrane and intracellular domains.
The hPD-L1 humanized model, developed by Knockin at the mouse Pd-L1 locus, expresses a chimeric PD-L1 (human extracellular domains and murine transmembrane and intracellular domains).
Both hPD-1 and hPD-L1 expressions are regulated by endogenous mouse promoters.
Splenocytes from hPD-1/hPD-L1 double homozygous mice and wild-type mice were activated with αCD3/αCD28 and cultured in presence of recombinant mIL-2. mPD-1 and hPD-1 expression was evaluated at day 0 and 2 on conventional CD4 T cells (viable, CD3+CD4+Foxp3-) and CD8 T cells (viable, CD3+CD8+Foxp3-).
Splenocytes from hPD-1/hPD-L1 and wild-type mice were treated or not (NT) for 24 hours with recombinant mouse IFN-γ. Fluorescence intensity (MFI) of mPD-L1 and hPD-L1 was evaluated on monocytes (CD3-CD19-CD11c-CD11b+) and T cells (viable, CD3+CD19-).
VISTA - safety and PK profiling
Humanized ICP mouse and cell lines
PLoS One
J Allergy Clin Immunol
J Immunother Cancer
Nat Cancer
The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.
Let us know how we can help